About Dennis Podlesak
Dennis Podlesak is a director at Syndax Pharmaceuticals.
Form D filings name Dennis Podlesak as a chief executive officer and director at Transposon Therapeutics.
Dennis Podlesak reports to the SEC as a director of 5 public companies, including Adynxx (ADYX), Tobira Therapeutics (TBRA) and Avanir Pharmaceuticals (AVNR).
Dennis Podlesak first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Dennis Podlesak in the role, so the role may have started earlier or lasted longer.
SI
Syndax Pharmaceuticals Inc
Director
2016 – 2026 · Public company (SNDX)
AI
Adynxx, Inc.
Director
2019 · Public company (ADYX)
TI
Tobira Therapeutics, Inc.
Director
2013 – 2016 · Public company (TBRA)
AI
Avanir Pharmaceuticals, Inc.
Director
2006 – 2014 · Public company (AVNR)
DI
Dov Pharmaceutical Inc.
Director
2006 – 2008 · Public company (DOVP)
Key Colleagues at Startups
The people Dennis Podlesak works with at each company, as listed on that company's latest Form D.
Transposon Therapeutics, Inc. · Form D, Jul 15, 2024
KK
Keith Katkin
Director
LR
Lynne Rollins
Executive officer
DM
Daniel Hetu, MD, MBA
Director
EM
Eckard Weber, MD
Executive officer and director
BA
Brent Ahrens
Director
BM
Brian Slingsby, MD, PHD, MPH
Director
WM
William Harrington, MD, MBA
Director
JP
John Pacifico
Director